For the first time, we showed that PDL1 was differentially expressed across the major breast cancer molecular subtypes, with more frequent upregulation in basal and ERBB2-enriched subtypes than in luminal A, luminal B and normal-like subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.